Drugs / AMBROXOL ACEFYLLINATE
AMBROXOL ACEFYLLINATE
also known as
Acebrophylline · Ambromucil · Ambroxol theophyllinate · Ambroxol-theophylline-7-acetate · Broncomnes · Surfolase · Surfolase CR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02373891 | Apr → Jul 2014 | — | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02792946 | Nov 2015 → Jan 2016 | bronchitis | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02395913 Comparator | Jul → Sep 2013 | — | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Phase 1 | NCT01723891 Comparator | Nov 2012 → ? | — | Hyundai Pharmaceutical Co., LTD. | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMBROXOL ACEFYLLINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297663 ↗ |
| Known as | Acebrophylline | “Acebrophylline is metabolized by being separated into Ambroxol and 7-theophylline when orally administered as a salt composed of an acid-base as a compound that was synthesized...” NCT02395913 ↗ |
| Known as | Ambromucil | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297663 ↗ |
| Known as | Ambroxol theophyllinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297663 ↗ |
| Known as | Ambroxol-theophylline-7-acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297663 ↗ |
| Known as | Broncomnes | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297663 ↗ |
| Known as | Surfolase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01723891 ↗ |
| Known as | Surfolase CR | “Surfolase CR (Acebrophylline 200mg) administration after fat intake” NCT02373891 ↗ |
| Action | Inhibit | “Acebrophylline is selectively applied to the bronchial or lung tissue and inhibit the activity of phospholipase bronchoalveolar” NCT02395913 ↗ |
| Modality | Small molecule | — CHEMBL4297663 ↗ |
| Route | Oral | “when orally administered” NCT02395913 ↗ |